肺大细胞神经内分泌癌化疗方案的选择是否影响生存
本研究基于荷兰癌症登记和病理登记数据,纳入2003-2012年IV期化疗治疗的肺大细胞神经内分泌癌(LCNEC)患者,经病理复核确诊128例。比较含铂方案中NSCLC-t(吉西他滨/多西他赛/紫杉醇/长春瑞滨)、NSCLC-pt(培美曲塞)和SCLC-t(依托泊苷)的生存,NSCLC-t中位总生存8.5个月,显著优于NSCLC-pt的5.9个月和SCLC-t的6.7个月。
要点
- 在病理复核确诊的IV期LCNEC患者中,NSCLC-t化疗的中位总生存最长。
- NSCLC-pt和SCLC-t方案的中位生存均短于NSCLC-t,风险比支持NSCLC-t。
- 本研究为回顾性分析,化疗方案选择需结合病理复核结果个体化评估。
核心结论
- 在LCNEC患者中,NSCLC-t化疗相比NSCLC-pt和SCLC-t化疗可获得更长的总生存。
研究设计与样本
- 基于荷兰癌症登记和荷兰病理登记(PALGA)检索2003-2012年IV期化疗治疗的LCNEC患者。
- 207例患者有组织学切片供病理专家组复核,其中128例确诊为LCNEC并纳入分析。
主要发现
- NSCLC-t化疗使用率为46%(n=60),NSCLC-pt为16%(n=20),SCLC-t为38%(n=48)。
- NSCLC-t中位总生存为8.5个月(95%CI 7.0-9.9)。
- NSCLC-pt中位总生存为5.9个月(95%CI 5.0-6.9),对比NSCLC-t的风险比为2.51(95%CI 1.39-4.52;p=0.002)。
- SCLC-t中位总生存为6.7个月(95%CI 5.0-8.5),对比NSCLC-t的风险比为1.66(95%CI 1.08-2.56;p=0.020)。
临床怎么用
- 对于病理复核确诊的IV期LCNEC,含铂NSCLC-t方案(吉西他滨、多西他赛、紫杉醇或长春瑞滨)可能优于培美曲塞方案或SCLC-t方案。
- 化疗方案选择前应重视病理复核,避免仅凭初始诊断决定治疗方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pulmonary large cell neuroendocrine carcinoma (LCNEC) is rare. Chemotherapy for metastatic LCNEC ranges from small cell lung carcinoma (SCLC) regimens to nonsmall cell lung carcinoma (NSCLC) chemotherapy regimens. We analysed outcomes of chemotherapy treatments for LCNEC.The Netherlands Cancer Registry and Netherlands Pathology Registry (PALGA) were searched for patients with stage IV chemotherapy-treated LCNEC (2003-2012). For 207 patients, histology slides were available for pathology panel review. First-line platinum-based combined chemotherapy was clustered as "NSCLC-t", comprising gemcitabine, docetaxel, paclitaxel or vinorelbine; "NSCLC-pt", with pemetrexed treatment only; and "SCLC-t", consisting of etoposide chemotherapy.A panel review diagnosis of LCNEC was established in 128 out of 207 patients. NSCLC-t chemotherapy was administered in 46% (n=60), NSCLC-pt in 16% (n=20) and SCLC-t in 38% (n=48) of the patients. The median (95% CI) overall survival for NSCLC-t chemotherapy was 8.5 (7.0-9.9) months, significantly longer than patients treated with NSCLC-pt, with a median survival of 5.9 (5.0-6.9) months (hazard ratio 2.51, 95% CI 1.39-4.52; p=0.002) and patients treated with SCLC-t chemotherapy, with a median survival of 6.7 (5.0-8.5) months (hazard ratio 1.66, 95% CI 1.08-2.56; p=0.020).In patients with LCNEC, NSCLC-t chemotherapy results in longer overall survival compared to NSCLC-pt and SCLC-t chemotherapy.
引用
- Derks JL, van Suylen RJ, Thunnissen E, et al. Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter? Eur Respir J. 2017. PMID: 28572122. doi:10.1183/13993003.01838-2016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。